MCID: SCL003
MIFTS: 49

Social Phobia

Categories: Mental diseases

Aliases & Classifications for Social Phobia

MalaCards integrated aliases for Social Phobia:

Name: Social Phobia 12 15
Phobia, Social 44 73
Phobic Anxiety Disorder 73
Phobia Social 55

Classifications:



External Ids:

Disease Ontology 12 DOID:11257
ICD10 33 F40.1 F40.10
ICD9CM 35 300.23
MeSH 44 D000072861
NCIt 50 C34927
SNOMED-CT 68 25501002

Summaries for Social Phobia

Disease Ontology : 12 A phobic disorder that involves social anxiety occurring only in specific public or social situations, interactions with others or being evaluated or scrutinized by other people.

MalaCards based summary : Social Phobia, also known as phobia, social, is related to avoidant personality disorder and anxiety. An important gene associated with Social Phobia is MAOA (Monoamine Oxidase A), and among its related pathways/superpathways are Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways and Serotonergic synapse. The drugs Vortioxetine and Norepinephrine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and amygdala, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Social Phobia

Diseases related to Social Phobia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 117)
# Related Disease Score Top Affiliating Genes
1 avoidant personality disorder 31.2 MAOA SLC6A4
2 anxiety 31.2 HTR1A HTR3A MAOA SLC6A4
3 depression 31.1 HTR1A MAOA SLC6A4
4 agoraphobia 30.8 HTR1A MAOA SLC6A4
5 panic disorder 30.5 CCK HTR1A HTR3A MAOA SLC6A4
6 personality disorder 30.4 DRD2 HTR1A MAOA PRL SLC6A4
7 generalized anxiety disorder 30.1 DRD2 HTR1A HTR3A MAOA SLC6A4
8 paraphilia disorder 30.0 MAOA PRL
9 premature ejaculation 30.0 HTR1A HTR3A SLC6A4
10 borderline personality disorder 29.8 HTR1A MAOA SLC6A4
11 alexithymia 29.8 DRD2 HTR1A SLC6A4
12 mood disorder 29.7 DRD2 HTR1A MAOA SLC6A4
13 eating disorder 29.7 CCK DRD2 SLC6A4
14 autism 29.7 DRD2 HTR1A MAOA SLC6A4
15 obsessive-compulsive disorder 29.7 DRD2 HTR1A HTR3A MAOA PRL SLC6A4
16 drug dependence 29.6 DRD2 SLC6A4
17 alcohol abuse 29.6 DRD2 PRL SLC6A4
18 attention deficit-hyperactivity disorder 29.3 DRD2 HTR1A MAOA SLC6A4
19 major depressive disorder 29.1 DRD2 HTR1A HTR3A MAOA PRL SLC6A4
20 schizophrenia 29.0 CCK DRD2 HTR1A HTR3A MAOA PRL
21 bipolar disorder 28.9 DRD2 HTR1A HTR3A MAOA PRL SLC6A4
22 alcohol dependence 28.7 CCK DRD2 HTR1A HTR3A MAOA SLC6A4
23 mutism 10.3
24 elective mutism 10.3
25 strabismus 10.2
26 phobia, specific 10.2
27 stuttering 10.2
28 body dysmorphic disorder 10.2
29 separation anxiety disorder 10.2
30 atypical depressive disorder 10.1 MAOA SLC6A4
31 dysthymic disorder 10.1 MAOA SLC6A4
32 paranoid schizophrenia 10.1 MAOA SLC6A4
33 neurofibromatosis, type ii 10.1
34 torticollis 10.1
35 retinal dystrophy, iris coloboma, and comedogenic acne syndrome 10.1
36 cervical dystonia 10.1
37 essential tremor 10.1
38 tremor 10.1
39 psychosexual disorder 10.1 HTR1A SLC6A4
40 stereotypic movement disorder 10.0 CCK PRL
41 rumination disorder 10.0 HTR1A HTR3A
42 motion sickness 10.0 HTR1A HTR3A
43 bipolar i disorder 10.0 HTR1A SLC6A4
44 postpartum depression 10.0 MAOA PRL SLC6A4
45 amnestic disorder 10.0 HTR1A HTR3A
46 galactorrhea 10.0 DRD2 PRL
47 schizophreniform disorder 10.0 DRD2 PRL
48 functional gastric disease 10.0 CCK HTR3A
49 prolactin producing pituitary tumor 10.0 DRD2 PRL
50 phobic disorder 10.0 HTR1A MAOA SLC6A4

Comorbidity relations with Social Phobia via Phenotypic Disease Network (PDN):


Anxiety Dysthymic Disorder

Graphical network of the top 20 diseases related to Social Phobia:



Diseases related to Social Phobia

Symptoms & Phenotypes for Social Phobia

GenomeRNAi Phenotypes related to Social Phobia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.28 HTR1A HTR3A SLC6A4
2 Decreased viability GR00381-A-3 9.28 HTR1A HTR3A SLC6A4
3 Decreased viability GR00402-S-2 9.28 HTR1A HTR3A SLC6A4

MGI Mouse Phenotypes related to Social Phobia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.8 CCK DRD2 HTR1A HTR3A MAOA PRL
2 endocrine/exocrine gland MP:0005379 9.55 CCK DRD2 HTR3A PRL SLC6A4
3 homeostasis/metabolism MP:0005376 9.5 CCK DRD2 HTR1A HTR3A MAOA PRL
4 nervous system MP:0003631 9.17 CCK DRD2 HTR1A HTR3A MAOA PRL

Drugs & Therapeutics for Social Phobia

Drugs for Social Phobia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 195)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vortioxetine Approved, Investigational Phase 4 508233-74-7 9966051
2
Norepinephrine Approved Phase 4,Phase 3,Not Applicable 51-41-2 439260
3
Citalopram Approved Phase 4,Phase 2,Phase 1,Not Applicable 59729-33-8 2771
4
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61869-08-7 43815
5
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-61-6, 62-31-7 681
6
Ketamine Approved, Vet_approved Phase 4,Early Phase 1 6740-88-1 3821
7
Sertraline Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 79617-96-2 68617
8
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
9
Cycloserine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 68-41-7 6234 401
10
Tiagabine Approved, Investigational Phase 4 115103-54-3 60648
11
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
12
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
13
Ethanol Approved Phase 4,Phase 2,Not Applicable 64-17-5 702
14 Piracetam Approved, Investigational Phase 4,Phase 2 7491-74-9
15
Propranolol Approved, Investigational Phase 4,Phase 2,Not Applicable 525-66-6 4946
16
Guanfacine Approved, Investigational Phase 4,Phase 2 29110-47-2 3519
17
Topiramate Approved Phase 4 97240-79-4 5284627
18
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
19
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
20
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
21
Acetylcholine Approved Phase 4 51-84-3 187
22 Etiracetam Investigational Phase 4,Phase 2 33996-58-6
23 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
24 Tranquilizing Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
25 Serotonin Antagonists Phase 4,Phase 2
26 Anti-Anxiety Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
28 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Serotonin 5-HT1 Receptor Agonists Phase 4,Not Applicable
31 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Serotonin 5-HT3 Receptor Antagonists Phase 4
34 Venlafaxine Hydrochloride Phase 4,Phase 3,Not Applicable
35 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
36 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4,Phase 3,Not Applicable
37 Antidepressive Agents, Second-Generation Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
39 Parasympatholytics Phase 4,Phase 2,Phase 1,Not Applicable
40 Cholinergic Agents Phase 4,Phase 2,Phase 1,Not Applicable
41 Cholinergic Antagonists Phase 4,Phase 2,Phase 1,Not Applicable
42 Muscarinic Antagonists Phase 4,Phase 2,Phase 1,Not Applicable
43 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Dopamine Agents Phase 4,Phase 3,Phase 2,Not Applicable
48 Analgesics Phase 4,Phase 3,Early Phase 1,Not Applicable
49 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
50 Excitatory Amino Acids Phase 4,Phase 3,Phase 2,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 343)
# Name Status NCT ID Phase Drugs
1 Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder Unknown status NCT02294305 Phase 4 Vortioxetine;Placebo
2 Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder Completed NCT00282828 Phase 4 Sertraline;Venlafaxine;Placebo;Clonazepam
3 The Use of Quetiapine (Seroquel) in the Treatment of Social Phobia: Public Speaking Environment Completed NCT00407199 Phase 4 quetiapine
4 D-Cycloserine Enhancement of Exposure in Social Phobia Completed NCT00633984 Phase 4 D-Cycloserine;Placebo
5 Nefazodone in the Treatment of Social Phobia Completed NCT00231348 Phase 4 Nefazodone
6 12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder Completed NCT01316302 Phase 4 Pristiq;Placebo
7 Study To Evaluate The Effects Of Gabitril™ In Patients With Social Anxiety Disorder Completed NCT00208741 Phase 4 Gabitril
8 Escitalopram in Patients With Social Anxiety Disorder Completed NCT00902226 Phase 4 Escitalopram
9 Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults Completed NCT01224067 Phase 4 Quetiapine
10 Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism Completed NCT00246441 Phase 4 Paroxetine;Placebo
11 Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder Completed NCT00190879 Phase 4 Atomoxetine hydrochloride;placebo
12 RCT of Cognitive Therapy, Paroxetine, Combined CT and Paroxetine and Placebo Completed NCT00184106 Phase 4 Seroxat, Cognitive therapy, Seroxat+ cognitive therapy
13 Primary Care Intervention Strategy for Anxiety Disorders Completed NCT00347269 Phase 4 Psychotropic medication optimization
14 Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety Completed NCT00177008 Phase 4 Aripiprazole
15 Acamprosate in Alcoholics With Comorbid Anxiety or Depression Completed NCT00330174 Phase 4 Acamprosate
16 Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder Completed NCT00265109 Phase 4 Levetiracetam
17 Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity Completed NCT01863459 Phase 4 Lisdexamfetamine Dimesylate;placebo
18 Efficacy of Adding Topiramate to Current Treatment in Treatment-Resistant Generalized Social Phobia (GSP) Recruiting NCT00182455 Phase 4 Topiramate;Placebo
19 Gabapentin for Pain Management During Dilation and Evacuation Recruiting NCT03635905 Phase 4 Gabapentin;Placebo
20 Treatments for Anxiety: Meditation and Escitalopram Recruiting NCT03522844 Phase 4 Escitalopram
21 Brief Intervention to Reduce Fear of Public Speaking Active, not recruiting NCT02790736 Phase 4 propranolol;Placebo
22 Ketamine Infusion for Adolescent Depression and Anxiety Active, not recruiting NCT02579928 Phase 4 Ketamine;Midazolam
23 A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) Active, not recruiting NCT03348618 Phase 4
24 A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity Not yet recruiting NCT03785223 Phase 4 Methylphenidate Hydrochloride Controlled-Release Capsules;Placebo Capsule
25 Guanfacine Extended Release and Mindfulness Skills Therapy Not yet recruiting NCT03258476 Phase 4 Guanfacine Extended Release;Placebo
26 A Study of the Efficacy of Botox in the Treatment of Social Anxiety Disorder Terminated NCT03078270 Phase 4 botulinum toxin A
27 Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders Terminated NCT00182533 Phase 4 Sertraline;Placebo
28 Transfer of Manualized Cognitive-Behavioral Therapy (CBT) for Social Phobia Into Clinical Practice Unknown status NCT01388231 Phase 2, Phase 3
29 Treatment of Social Phobia and Panic Disorder in Adults Completed NCT00619138 Phase 3
30 Residential Cognitive and Interpersonal Therapy for Social Phobia Completed NCT00326430 Phase 2, Phase 3
31 Treatment of Childhood Social Phobia Completed NCT00043537 Phase 3 Fluoxetine;Pill Placebo
32 A Comparison Between Internet Therapy and Group Therapy for Social Phobia - A Trial Using Cognitive Behavioural Therapy Completed NCT00564967 Phase 3
33 Quetiapine in Social Anxiety Disorder Completed NCT00215254 Phase 2, Phase 3 quetiapine
34 Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia Completed NCT00515879 Phase 3 D-cycloserine;Placebo
35 Social Anxiety Disorder Study Of Paroxetine Completed NCT00318669 Phase 3 Paroxetine hydrochloride hydrate
36 Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD) Completed NCT02622958 Phase 3 PH94B
37 Flushing in Social Anxiety Disorder on Seroquel Completed NCT00773162 Phase 3 Seroquel;Sugar Pill
38 Efficacy and Tolerability of Atomoxetine (Strattera) in Adult Patients With Generalized Social Anxiety Disorder Completed NCT00260533 Phase 2, Phase 3 atomoxetine;placebo
39 Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder Completed NCT00074802 Phase 3 Paroxetine
40 Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety Completed NCT00958880 Phase 3 Yohimbine Hydrochloride;Sugar Pill
41 Study Evaluating Venlafaxine ER in Children and Adolescents With Social Anxiety Disorder Completed NCT00238719 Phase 3 Venlafaxine ER
42 Long-term Study Of Paroxetine in Women and Men Completed NCT00264654 Phase 3 BRL29060A;paroxetine hydrochloride hydrate
43 Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome Completed NCT00114127 Phase 3 Duloxetine;Duloxetine;Placebo
44 St. John's Wort for the Treatment of Generalized Social Anxiety Disorder (GSAD) Completed NCT00118833 Phase 2, Phase 3 Hypericum perforatum (St. John's wort)
45 A Systems Level Intervention for Unemployed Persons With Social Anxiety Disorder Completed NCT01654510 Phase 2, Phase 3
46 A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder Completed NCT00411398 Phase 3 Namenda/Memantine
47 Treatment for Anxiety in Children Completed NCT00000389 Phase 3 Fluvoxamine
48 Computerized Cognitive Behavioral Therapy for Childhood Anxiety in Community Health Centers Completed NCT01416805 Phase 3
49 Child and Adolescent Anxiety Disorders (CAMS) Completed NCT00052078 Phase 3 Sertraline (SRT);Placebo
50 Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders Completed NCT01178385 Phase 2, Phase 3

Search NIH Clinical Center for Social Phobia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: phobia, social

Genetic Tests for Social Phobia

Anatomical Context for Social Phobia

MalaCards organs/tissues related to Social Phobia:

41
Brain, Testes, Amygdala, Heart, Cortex, Pituitary, Eye

Publications for Social Phobia

Articles related to Social Phobia:

(show top 50) (show all 1026)
# Title Authors Year
1
Measurement equivalence of the Social Interaction Anxiety Scale (SIAS) and Social Phobia Scale (SPS) across individuals with social anxiety disorder from Japanese and Australian sociocultural contexts. ( 30243196 )
2019
2
Psychometric Evaluation of the Social Phobia Inventory and the Mini-Social Phobia Inventory in a Swedish University Student Sample. ( 29375026 )
2018
3
Optimal Cut Points for Remission and Response for the German Version of the Social Phobia Anxiety Inventory (SPAI). ( 29862918 )
2018
4
Avoidant personality disorder and social phobia: Does mindreading make the difference? ( 29096207 )
2018
5
Well-being in major depression and social phobia with and without comorbidity. ( 30487925 )
2018
6
Bigger is better: Full-length versions of the Social Interaction Anxiety Scale and Social Phobia Scale outperform short forms at assessing treatment outcome. ( 30070558 )
2018
7
Examination of Executive Function and Social Phobia Among Female College-Aged Students With Celiac Disease. ( 30272808 )
2018
8
Comorbid social phobia does not predict the outcome in alcohol use disorder outpatient treatment. ( 30384322 )
2018
9
Prevalence and associated factors for social phobia among school-going adolescents in a rural area of Puducherry, South India. ( 30398971 )
2018
10
Identifying sub-categories of social fears using an alternative factor analytic structure of the Social Phobia and Anxiety Inventory. ( 28236783 )
2017
11
Confirmatory Factor Analysis of the Combined Social Phobia Scale and Social Interaction Anxiety Scale: Support for a Bifactor Model. ( 28210232 )
2017
12
Social phobia, depression and eating disorders during middle adolescence: longitudinal associations and treatment seeking. ( 28868945 )
2017
13
Comorbidity of schizophrenia and social phobia - impact on quality of life, hope, and personality traits: a cross sectional study. ( 28831256 )
2017
14
Collaborative care for panic disorder, generalised anxiety disorder and social phobia in general practice: study protocol for three cluster-randomised, superiority trials. ( 28814317 )
2017
15
Mini - social phobia inventory (mini-SPIN): psychometric properties and population based norms of the German version. ( 29178857 )
2017
16
Daily fluctuation of emotions and memories thereof: Design and methods of an experience sampling study of major depression, social phobia, and controls. ( 28948700 )
2017
17
Depression and social phobia in essential tremor and Parkinson's disease. ( 28948077 )
2017
18
Community-Based Validation of the Social Phobia Screener (SOPHS). ( 26939801 )
2017
19
Social Phobia: The Role of In-Situation Safety Behaviors in Maintaining Anxiety and Negative Beliefs - Republished Article. ( 27816079 )
2016
20
Autonomic markers associated with generalized social phobia symptoms: heart rate variability and salivary alpha-amylase. ( 27892761 )
2016
21
Selective Mutism: The Fraternal Twin of Childhood Social Phobia. ( 27089281 )
2016
22
Virtual reality exposure using three-dimensional images for the treatment of social phobia. ( 26561376 )
2016
23
The effect of Interaction Anxiousness Scale and Brief Social Phobia Scale for screening social anxiety disorder in college students: a study on discriminative validity. ( 27935389 )
2016
24
Social Phobia Is Associated with Delayed Onset of Chickenpox, Measles, and Mumps Infections. ( 28082921 )
2016
25
Examination of the Correlation Between Internet Addiction and Social Phobia in Adolescents. ( 27561297 )
2016
26
No effects of psychosocial stress on memory retrieval in non-treated young students with Generalized Social Phobia. ( 27464065 )
2016
27
Attentional mechanisms of social perception are biased in social phobia. ( 27131909 )
2016
28
Factor solutions of the Social Phobia Scale (SPS) and the Social Interaction Anxiety Scale (SIAS) in a Swedish population. ( 27894213 )
2016
29
Psychometric properties of the mini-social phobia inventory (Mini-SPIN) in a large online treatment-seeking sample. ( 27046641 )
2016
30
Assimilation, reflexivity, and therapist responsiveness in group psychotherapy for social phobia: A case study. ( 27092848 )
2016
31
Hypochondriasis Differs From Panic Disorder and Social Phobia: Specific Processes Identified Within Patient Groups. ( 27805984 )
2016
32
Retracted: Combined Case of Blood-Injury-Injection Phobia and Social Phobia: Behavior Therapy Management and Effectiveness through Tilt Test. ( 27722005 )
2016
33
Internet-based CBT for social phobia and panic disorder in a specialised anxiety clinic in routine care: Results of a pilot randomised controlled trial. ( 30135794 )
2016
34
Correction: The Neuroanatomical Basis of Panic Disorder and Social Phobia in Schizophrenia: A Voxel Based Morphometric Study. ( 25906143 )
2015
35
An experimental investigation of the functional relationship between social phobia and cigarette smoking. ( 25576952 )
2015
36
Social Phobia and Educational and Interpersonal Impairments in Adolescence: A Prospective Study. ( 26514560 )
2015
37
Behavioral treatment of social phobia in youth: Does parent education training improve the outcome? ( 25727679 )
2015
38
Correction: Avoidant Personality Disorder versus Social Phobia: The Significance of Childhood Neglect. ( 25978045 )
2015
39
Comparison of automatical thoughts among generalized anxiety disorder, major depressive disorder and generalized social phobia patients. ( 26241548 )
2015
40
Attachment styles in patients with avoidant personality disorder compared with social phobia. ( 26332087 )
2015
41
Reprint of: Social phobia and other psychiatric problems in children with strabismus. ( 26049893 )
2015
42
Intensive Group-Based CBT for Child Social Phobia: A Pilot Study. ( 25892171 )
2015
43
Social anxiety disorders in clinical practice: differentiating social phobia from avoidant personality disorder. ( 26129819 )
2015
44
Latent dimensions of social anxiety disorder: A re-evaluation of the Social Phobia Inventory (SPIN). ( 26454660 )
2015
45
Social phobia and quality of life in morbidly obese patients before and after bariatric surgery. ( 25863007 )
2015
46
Developmental Differences in Functioning in Youth With Social Phobia. ( 26630122 )
2015
47
Short-term Dynamic Psychotherapy versus Sertraline in Treatment of Social Phobia. ( 26288643 )
2015
48
The neuroanatomical basis of panic disorder and social phobia in schizophrenia: a voxel based morphometric study. ( 25774979 )
2015
49
Avoidant personality disorder versus social phobia: the significance of childhood neglect. ( 25815817 )
2015
50
The Efficacy of Self-Report Measures in Predicting Social Phobia in African American Adults. ( 27282718 )
2015

Variations for Social Phobia

Expression for Social Phobia

Search GEO for disease gene expression data for Social Phobia.

Pathways for Social Phobia

GO Terms for Social Phobia

Cellular components related to Social Phobia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.62 DRD2 HTR1A HTR3A SLC6A4
2 dendrite GO:0030425 9.43 CCK DRD2 HTR1A
3 axon GO:0030424 9.33 CCK DRD2 HTR3A
4 integral component of presynaptic membrane GO:0099056 9.13 DRD2 HTR3A SLC6A4
5 integral component of postsynaptic membrane GO:0099055 8.8 DRD2 HTR3A SLC6A4

Biological processes related to Social Phobia according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.5 DRD2 PRL SLC6A4
2 axonogenesis GO:0007409 9.49 CCK DRD2
3 circadian rhythm GO:0007623 9.48 PRL SLC6A4
4 response to nutrient GO:0007584 9.46 PRL SLC6A4
5 memory GO:0007613 9.43 CCK SLC6A4
6 excitatory postsynaptic potential GO:0060079 9.4 DRD2 HTR3A
7 visual learning GO:0008542 9.37 CCK DRD2
8 response to cocaine GO:0042220 9.26 DRD2 HTR3A
9 vasoconstriction GO:0042310 9.16 HTR1A SLC6A4
10 response to ethanol GO:0045471 9.13 DRD2 HTR3A PRL
11 serotonin receptor signaling pathway GO:0007210 8.62 HTR1A HTR3A

Molecular functions related to Social Phobia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serotonin binding GO:0051378 8.8 HTR1A HTR3A SLC6A4

Sources for Social Phobia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....